ERBB2 and carcinoma: Trastuzumab, a humanized monoclonal antibody to the HER2 protein, binds to the extracellular domain of HER2, which is localized in the cell membrane of carcinoma cells, and inhibits their proliferation by arresting the cell cycle during the G1 phase [9, 10].